Trade Mark Journal No.2024/050 13 December 2024

WO0000001825077 (5)

Office of origin: United States of America

Date of International Registration:24 October 2024
Date of designation in the UK: 24 October 2024
Image for mark 1825077 LOVMYEN

International priority date claimed: 28 June 2024 (United States of America) (98625107)
Class 5
Pharmaceutical preparations and substances for the treatment of neurological, neuropsychiatric, neurodegenerative, viral, metabolic, obesity, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, ophthalmic, respiratory, gastrointestinal, hormonal, dermatological, osteogenesis, immune system, central nervous system, peripheral nervous system, and voluntary muscle movement related diseases and disorders.

Biohaven Therapeutics Ltd.

Representative: Monica Riva Talley Sterne, Kessler, Goldstein & Fox P.L.L.C., 1101 K Street, N.W.,, 10th Floor, Washington DC 20005, UNITED STATES OF AMERICA